Insulet Corp.’s PODD groundbreaking Omnipod 5 Automated Insulin Delivery (“AID”) system (Omnipod 5) received the FDA’s approval for use by type 2 diabetes patients (ages 18 years and above).

Insulet develops, manufactures, and markets the Omnipod Insulin Management System for those with Type 2 diabetes. The system ...

Valued at a market cap of $18.5 billion, Insulet Corporation (PODD) develops, manufactures, and sells insulin delivery ...

Insulet Corporation’s PODD rapid progress with its strategic imperatives on Omnipod platform is poised to help it grow in the upcoming quarters. The largely untapped diabetes market also ...

In December, a Massachusetts corporation won the largest jury verdict ever awarded under the federal Defend Trade Secrets Act ...

CER growth exceeded the company’s guidance of 21%. Insulet’s total Omnipod revenues of $533.6 million reflected an increase of 26.4% year over year (up 26.1% at CER). International Omnipod ...

The lawsuit revolved around Insulet's Omnipod tubeless insulin pump – used with continuous glucose monitors (CGMs) to create an artificial pancreas system used by diabetics – and claimed that ...

Insulet's Omnipod The deal has been axed a few weeks after a federal judge in the US blocked EOFlow from selling its insulin patch pump in a lawsuit brought by Insulet, which sells a rival product.

Market open and close ceremonies take place daily at the Nasdaq MarketSite Studio in Times Square and around the globe. Insulet Corporation (Nasdaq: PODD), the global leader in tubeless insulin ...